Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AV-1980R in Preclinical Alzheimer's Disease
NCT07158905Phase 1Recruiting
- Sponsor
- Institute for Molecular Medicine
- Start
- Jun 2026
- Primary completion
- Jun 2029
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AV-1980R in Alzheimer's disease (AD) (4 arms), sponsored by Institute for Molecular Medicine. Primary endpoint: Number of Participants with Treatment-Emergent Adverse Events and Serious Adverse Events at 58 weeks. Started Jun 2026; status: recruiting.
02
Drugs
AV-1980R
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07158905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07158905.